The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes

Oncogene

Volumn 33, Issue 17, 2014, Pages 2157-2168

  Cai, Y ^a   Geutjes, E J ^b   De Lint, K ^b   Roepman, P ^c   Bruurs, L ^b   Yu, L R ^d   Wang, W ^a   Van Blijswijk, J ^b   Mohammad, H ^a   De Rink, I ^b   Bernards, R ^b   Baylin, S B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c Agendia NV   (Netherlands)

^d NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

colon cancer; DNMTs; NuRD; silencing; tumor suppressor genes; WNT signaling

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; NURD COMPLEX; PROTEIN CHD4; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CHD4 GENE; CHROMATIN ASSEMBLY AND DISASSEMBLY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DNMT1 GENE; DNMT3B GENE; EPIGENETICS; FUNCTIONAL GENOMICS; GENE; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOSOME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION SITE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; AUTOANTIGENS; AZACITIDINE; COLORECTAL NEOPLASMS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; EPIGENESIS, GENETIC; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, TUMOR SUPPRESSOR; HCT116 CELLS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HUMANS; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; WNT PROTEINS;

EID: 84899648475     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.178     Document Type: Article

References (51)

1. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome-components and functional correlates. Genes Dev 2006; 20: 3215-3231.
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
3. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057-1068.
4. Chodavarapu RK, Feng S, Bernatavichute YV, Chen PY, Stroud H, Yu Y et al. Relationship between nucleosome positioning and DNA methylation. Nature 2010; 466: 388-392.
5. Choy JS, Wei S, Lee JY, Tan S, Chu S, Lee TH. DNA methylation increases nucleosome compaction and rigidity. J Am Chem Soc 2010; 132: 1782-1783.
6. Lin JC, Jeong S, Liang G, Takai D, Fatemi M, Tsai YC et al. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 2007; 12: 432-444.
7. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21.
8. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998; 393: 386-389.
9. Lunyak VV, Burgess R, Prefontaine GG, Nelson C, Sze SH, Chenoweth J et al. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 2002; 298: 1747-1752.
10. Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H. The role of DNA methylation in setting up chromatin structure during development. Nat Genet 2003; 34: 187-192.
11. Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 1999; 13: 1924-1935.
12. Lai AY, Wade PA. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat Rev Cancer 2011; 11: 588-596.
13. Wade PA, Gegonne A, Jones PL, Ballestar E, Aubry F, Wolffe AP. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet 1999; 23: 62-66.
14. Myant K, Stancheva I. LSH cooperates with DNA methyltransferases to repress transcription. Mol Cell Biol 2008; 28: 215-226.
15. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006; 439: 871-874.
16. Mohammad HP, Cai Y, McGarvey KM, Easwaran H, Van Neste L, Ohm JE et al. Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer Res 2009; 69: 6322-6330.
17. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-1082.
18. Morey L, Brenner C, Fazi F, Villa R, Gutierrez A, Buschbeck M et al. MBD3, a component of the NuRD complex, facilitates chromatin alteration and deposition of epigenetic marks. Mol Cell Biol 2008; 28: 5912-5923.
19. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-556.
20. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.
21. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31: 141-149.
22. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36: 417-422.
23. Jurkin J, Zupkovitz G, Lagger S, Grausenburger R, Hagelkruys A, Kenner L et al. Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 2011; 10: 406-412.
24. Wilting RH, Yanover E, Heideman MR, Jacobs H, Horner J, van der Torre J et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J 2010; 29: 2586-2597.
25. Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29: 17-24.
26. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008; 14: 1669-1677.
27. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280: 168-176.
28. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
29. Reale A, Matteis GD, Galleazzi G, Zampieri M, Caiafa P. Modulation of DNMT1 activity by ADP-ribose polymers. Oncogene 2005; 24: 13-19.
30. Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 1997; 277: 1996-2000.
31. Esteve PO, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR et al. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 2006; 20: 3089-3103.
32. Schuebel KE, Chen W, Cope L, Glockner SC, Suzuki H, Yi JM et al. Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet 2007; 3: 1709-1723.
33. Ying Y, Tao Q. Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics 2009; 4: 307-312.
34. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin TJ et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer 2008; 98: 466-473.
35. Park M, Moon RT. The planar cell-polarity gene stbm regulates cell behaviour and cell fate in vertebrate embryos. Nat Cell Biol 2002; 4: 20-25.
36. Kaelin Jr WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-698.
37. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-5417.
38. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008; 7: 854-868.
39. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW. 5-Aza-2'-deoxycytidine- mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 2007; 26: 77-90.
40. Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat Genet 2003; 34: 145-147.
41. Phesse TJ, Parry L, Reed KR, Ewan KB, Dale TC, Sansom OJ et al. Deficiency of Mbd2 attenuates Wnt signaling. Mol Cell Biol 2008; 28: 6094-6103.
42. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994; 91: 11797-11801.
43. Polo SE, Kaidi A, Baskcomb L, Galanty Y, Jackson SP. Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. EMBO J 2010; 29: 3130-3139.
44. Smeenk G, Wiegant WW, Vrolijk H, Solari AP, Pastink A, van Attikum H. The NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage. J Cell Biol 2010; 190: 741-749.
45. Larsen DH, Poinsignon C, Gudjonsson T, Dinant C, Payne MR, Hari FJ et al. The chromatin-remodeling factor CHD4 coordinates signaling and repair after DNA damage. J Cell Biol 2010; 190: 731-740.
46. Huss M, Wieczorek H. Inhibitors of V-ATPases: old and new players. J Exp Biol 2009; 212(Pt 3): 341-346.
47. Huang Y, Stewart TM, Wu Y, Baylin SB, Marton LJ, Perkins B et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res 2009; 15: 7217-7228.
48. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105-1111.
49. Clements EG, Mohammad HP, Leadem BR, Easwaran H, Cai Y, Van Neste L et al. DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res 2012; 40: 4334-4346.
50. Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE et al. Distinct roles of GCN5/ PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J 2011; 30: 249-262.
51. Yu LR, Zhu Z, Chan KC, Issaq HJ, Dimitrov DS, Veenstra TD. Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra. J Proteome Res 2007; 6: 4150-4162.